Compare TransMedics Group Inc (TMDX) vs Vanguard Total Stock Market Index Fund ETF (VTI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs Vanguard Total Stock Market Index Fund ETF — how do they compare? TransMedics Group Inc trades at $78.19 (market cap $2.74B), while Vanguard Total Stock Market Index Fund ETF trades at $382.2 (market cap $2.30T). The key difference: Vanguard Total Stock Market Index Fund ETF is far larger — about 839.4× TransMedics Group Inc's market cap, and Vanguard Total Stock Market Index Fund ETF is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold TransMedics Group Inc for 24 Days and Vanguard Total Stock Market Index Fund ETF for 131 Days on average.
| TMDX | VTI | |
|---|---|---|
Market Cap | $2.74B | $2.30T |
Volume | 949,331 | 2,982,924 |
Sector | Health | — |
52-Week High | $150.42 | $384.30 |
52-Week Low | $61.99 | $311.68 |
Typical Hold Time | 24 Days | 131 Days |
Enterprise Value | $3.13B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TransMedics Group (TMDX) trades at $78.17, down 3.58% on the day, with a bearish technical signal and mixed earnings history. The company reported strong 2025 results with $605.49M revenue and $190.29M net income, but 2026 projections show margin compression. Recent news highlights insider buying and leadership changes alongside legal investigations into fiduciary duties, creating a complex sentiment backdrop.
The stock offers growth potential with a consensus price target of $99.75, but faces risks from earnings misses, margin pressure, and ongoing legal scrutiny. Analyst consensus remains bullish with 69% buy ratings, yet investors must weigh robust profitability metrics against execution and regulatory uncertainties.
VTI trades at $381.82, up 0.21% today, with a bullish technical signal from moving averages and neutral oscillators. The ETF shows strong institutional interest and broad diversification across the U.S. stock market. Recent news highlights its long-term growth potential and cost efficiency, with a dividend scheduled for September 2026.
The outlook for VTI remains positive due to its low-cost structure and exposure to the entire U.S. equity market. Risks include concentration in top holdings and market volatility, but its historical performance supports a solid foundation for long-term investors seeking diversified growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About Vanguard Total Stock Market Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the index, which represents approximately 100% of the investable US stock market and includes large-, mid-, small-, and micro-cap stocks. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the full index in terms of key characteristics.
Read more on VTI →
